Akari Therapeutics Plc: BANK OF MONTREAL amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Bank of Montreal has amended its Schedule 13G beneficial ownership filing for Akari Therapeutics Plc, per SEC accession 0000927971-26-000112. The filing updates the bank's reported stake in the clinical-stage biotech, though the headline disclosure did not specify the revised share count or percentage. Schedule 13G amendments are typically filed by institutional investors when their ownership position changes materially or passively crosses reporting thresholds. Investors will watch for the detailed filing to confirm whether Bank of Montreal increased, trimmed or maintained its Akari position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bank of Montreal, Akari Therapeutics Plc